Shawna Kraft earned her PharmD from the University of Michigan College of Pharmacy and completed a PGY-1 and PGY-2 in oncology at U-M Hospitals and Health Centers (UMHHC). She took care of inpatients as a clinical specialist in hematology/oncology for several years before assuming her current role in the clinic setting at U-M’s Comprehensive Cancer Center.

Professor Kraft provides didactic education on several topics, including oncologic and non-oncologic pain management, breast cancer, leukemias and lymphomas. She presents regularly at local, regional, and national conferences on multiple myeloma, oral chemotherapy, and symptom management topics. She is a board certified oncology pharmacist and the program director for the PGY-2 in oncology at UMHHC. She is also a member of the U-M College of Pharmacy Board of Governors and an active member of the American Society of Health-System Pharmacists, American College of Clinical Pharmacy, Hematology/Oncology Pharmacists Association, Michigan Society of Health System Pharmacists, and Michigan Pharmacists Association.  

Research Interests

  • Supportive care and symptom management in patients with cancer

  • Medical marijuana, oral chemotherapy, and antidepressants in cancer patients


  • 2022 2022 Michigan Center for IPE Award for Innovation and Excellence , IPE Center
  • 2019 MSHP President's Award, MSHP
  • 2017 P3 Faculty appreciation award, Student (sponsored by PDC)

Selected Publications

  • Kraft S, Baker N, Carpenter J, Bostwick J. Procarbazine and antidepressants: A retrospective review of the risk of serotonin toxicity. Psych-Oncology (accepted, undergoing revisions).

  • Koselke E, Kraft S. Chemotherapy induced diarrhea: Options for treatment and prevention. J Hem/Onc Pharm. 2012 Dec; 2(4):143-151.

  • Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemotherapy. 2012 Aug 21. [Epub ahead of print].

  • Kraft SL, Johnson CE, Tyler R. Stability of oral liquid preparation of thalidomide 20 mg/mL in syrup. Am J Health Syst Pharm. 2012 Jan 1; 69(1):56-8.